1952.HK
Price:
$45.6
Market Cap:
$13.67B
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
Industry
Biotechnology
IPO Date
2020-10-09
Stock Exchange
HKSE
Ticker
1952.HK
According to Everest Medicines Limited’s latest financial reports and current stock price. The company's current PE Ratio is -13.41. This represents a change of 42.08% compared to the average of -9.44 of the last 4 quarters.
The mean historical PE Ratio of Everest Medicines Limited over the last ten years is -23.30. The current -13.41 PE Ratio has changed 5.66% with respect to the historical average. Over the past ten years (40 quarters), 1952.HK's PE Ratio was at its highest in in the March 2019 quarter at 44.48. The PE Ratio was at its lowest in in the June 2021 quarter at -24.50.
Average
-23.30
Median
-14.01
Minimum
-95.29
Maximum
-2.15
Discovering the peaks and valleys of Everest Medicines Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 421.74%
Maximum Annual PE Ratio = -2.15
Minimum Annual Increase = -97.74%
Minimum Annual PE Ratio = -95.29
Year | PE Ratio | Change |
---|---|---|
2024 | -14.01 | 99.53% |
2023 | -7.02 | -61.99% |
2022 | -18.47 | 134.72% |
2021 | -7.87 | 265.85% |
2020 | -2.15 | -97.74% |
2019 | -95.29 | 421.74% |
The current PE Ratio of Everest Medicines Limited (1952.HK) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-13.17
5-year avg
-9.90
10-year avg
-23.30
Everest Medicines Limited’s PE Ratio is greater than Shanghai Junshi Biosciences Co., Ltd. (-22.80), less than Ocumension Therapeutics (-12.85), greater than InnoCare Pharma Limited (-31.84), greater than Innovent Biologics, Inc. (-812.91), greater than Akeso, Inc. (-124.44),
Company | PE Ratio | Market cap |
---|---|---|
-22.80 | $26.37B | |
-12.85 | $4.26B | |
-31.84 | $14.21B | |
-812.91 | $82.48B | |
-124.44 | $72.52B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Everest Medicines Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Everest Medicines Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Everest Medicines Limited's PE Ratio?
How is the PE Ratio calculated for Everest Medicines Limited (1952.HK)?
What is the highest PE Ratio for Everest Medicines Limited (1952.HK)?
What is the 3-year average PE Ratio for Everest Medicines Limited (1952.HK)?
What is the 5-year average PE Ratio for Everest Medicines Limited (1952.HK)?
How does the current PE Ratio for Everest Medicines Limited (1952.HK) compare to its historical average?